CS Paper Radar

Semi-Supervised Learning-Based Genetic Biomarkers Dataset for Multiple-Stage Hepatocellular Carcinoma Prediction

Ahmed Ammar Kubba, Manar Abu Talib, Jibran Sualeh Muhammad, Ali Bou Nassif, Abdalla Sayed Mohamed, Darko Castven, Jens U. Marquardt

cs.AI ·submitted 2026-09-15 12:33 UTC · v1
published

Abstract

Liver cancer is a complex disease responsible for a high number of deaths across the globe each year, making automated solutions for liver cancer classification urgent. The most common form of liver cancer is hepatocellular carcinoma (HCC), accounting for over 90% of liver cancer cases. There is a distinct lack of publicly available HCC datasets utilizing genomic data, which is necessary for training artificial intelligence (AI) models for automated HCC classification. This study proposes constructing a multi-stage HCC dataset using XGBoost and Semi-Supervised learning on three separate datasets of genomic biomarkers, utilizing their existing labels in the Semi-Supervised learning process to label the proposed dataset. The proposed dataset consists of 770 patient samples in total, categorized into five classes that represent normal tissue alongside different stages of HCC. Each sample in the dataset consists of 11,150 different gene expression levels. The XGBoost model demonstrated a final classification accuracy of 96.5% during the Semi-Supervised learning process.

Comment
6 pages, 7 figures, 2 tables, published at the 18th International Conference Series on Developments in eSystems Engineering
Journal ref
2025 18th International Conference on Development in eSystem Engineering (DeSE), Bucharest, Romania, 2025, pp. 555-560
DOI
10.1109/DeSE68208.2025.11368219

Closest papers

Nearest neighbours by meaning across the whole index.

Potential of Artificial Intelligence Algorithms for Identification of Relevant Diagnostic and Prognostic Biomarkers of Early-Stage Liver Cancer

cs.AI ·2026-09-14 ·Ali Bou Nassif, Darko Castven, Manar Abu Talib, Jibran Sualeh Muhammad, Ahmed Ammar Kubba +2 more
hot direction similarity 0.82
Abstract · 25 pages, 11 figures, 4 tables, under review

This study explores the use of deep learning and explainable artificial intelligence to diagnose hepatocellular carcinoma (HCC) and define effective biomarkers across five different stages of disease development using a transcriptomic biomarker HCC dataset constructed via semi-supervised learning from three source datasets. Several deep learning experiments were conducted with different feature extraction techniques and gene sets to identify the most effective features for training high-accuracy models with minimal loss. The best-performing model, using 15 selected genes with the SelectKBest algorithm, achieved 90.74% accuracy, while the model with the lowest recorded loss of 0.3187 was obtained using 20 selected genes. To address the issue of class imbalance in the dataset, a weighted training approach was conducted, and for model transparency and interpretability a SHAP-based XAI analysis provided insights into the model's decision-making, consistently finding DNAJB14 as the most influential gene. Functional validation in this study has provided compelling evidence that DNAJB14 plays an important role in the adverse properties of HCC and that its inhibition effectively reverses tumour cell migration, invasion, colony and sphere formation. The main limitation of this study is the dataset's class imbalance, and while weighted training helped mitigate this, further research and additional data are needed to guarantee model generalizability. Future studies should also explore the influence of genetic variations, environmental factors, and clinical differences on model performance across diverse populations.

0.34

AMPLIFAI: A Multiphase CT Dataset for Benchmarking Clinical Reasoning in LI-RADS Assessment of Liver Lesions

cs.CV cs.LG ·2026-08-14 ·Pranav Kulkarni, Nikhil Shah, Amritansh Suryavanshi, Jana G. Delfino, James Tonascia +7 more
dataset similarity 0.64
Abstract · 15 pages, 6 figures, 3 tables

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide, with early detection improving survival from <20% to >70%. The standardized Liver Imaging Reporting and Data System (LI-RADS) criteria provide an imaging-based diagnostic framework to evaluate liver lesions for HCC, serving as a foundation for automating HCC detection with artificial intelligence (AI). However, the lack of large, publicly available datasets with high-quality annotations has limited the development and evaluation of AI models for automated LI-RADS assessment. We introduce AMPLIFAI dataset, the first public dataset of 590 multiphase abdominal CT studies annotated with LI-RADS categories, lesion size, and voxel-level segmentations for three major LI-RADS features: arterial phase hyperenhancement, washout, and enhancing capsule. The dataset was curated and harmonized from four public datasets and augmented with expert annotations from five board-certified radiologists and one resident. Following the Datasheets for Datasets format, this paper details the dataset's composition, curation and harmonization process, and annotation workflow to support transparent, reproducible research in medical imaging AI.

0.10

An interpretable deep learning method for early hepatocellular carcinoma diagnosis on multiphase CT

cs.CV cs.AI ·2026-10-21 ·Emma Sarfati, Alexandre Bône, Pietro Gori, Sisi Yang, Marc-Michel Rohé +6 more
publishedhot direction similarity 0.62
Abstract · Accepted at Scientific Reports

Early diagnosis of hepatocellular carcinoma is critical to preserve access to curative treatment options. The Liver Imaging Reporting and Data System (LI-RADS) provides a standardized framework for non-invasive diagnosis on multiphase computed tomography, based on major visual imaging features. However, these features may be difficult to assess consistently, particularly in small liver lesions. We developed dLI-RADS, an interpretable artificial intelligence method designed to estimate the probability of hepatocellular carcinoma from multiphase computed tomography images of manually segmented liver lesions, while remaining aligned with LI-RADS-related imaging concepts. dLI-RADS combines neural network-derived predictions with handcrafted quantitative imaging measurements reflecting LI-RADS major features and integrates these inputs using logistic regression. In this multicenter retrospective study, patients with multiphase computed tomography and at least one liver lesion were included, while lesions larger than 40 mm were excluded. Histology served as the reference standard for hepatocellular carcinoma, and a composite reference standard was used for non-hepatocellular carcinoma lesions. The lesion-level accuracy of dLI-RADS and LI-RADS were compared on the internal evaluation set using 10,000-repetition bootstrap non-inferiority tests, with 5% margins and significance levels. On the external test set, sensitivities were similarly compared. dLI-RADS was non-inferior to LI-RADS for lesion-level accuracy in the internal evaluation set, achieving 80% accuracy compared with 74% for LI-RADS (p = 0.04)...

0.29

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

cs.AI ·2026-10-02 ·Jungkyu Park, Dhruva Biswas, Joseph Cappadona, Cerise Tang, Ken G. Zeng +20 more
similarity 0.59
Abstract

Scarcity of labeled data limits development of deep learning biomarkers in oncology. We develop a two-stage AI model predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer. The first stage learns the transcriptome from histopathology using 8,742 patients across 32 cancer types, corroborated by pathologist review and spatial agreement with measured expression. This simplifies the second stage to predicting pCR from inferred expression and clinical variables. Developed using 1,080 patients (five cohorts) and evaluated in 1,412 patients (nine cohorts), the model achieves a pooled AUROC of 0.79 (95% CI, 0.73-0.85), discriminating responders within molecular subtypes. It outperforms histopathological biomarkers, remaining stable across intratumoral sampling and with minimal biopsy tissue. Ablations show transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays' gene selection constraints. These results indicate that biologically informed compression may generalize to data-sparse applications in precision oncology.

0.06

ECG2Gene: Deep Learning-Based Germline Tumor Susceptibility Gene Risk Assessment Using Electrocardiograms

cs.LG ·2026-10-31 ·Shanwei Zhang, Qinghao Zhao, Yize Zhao, Jun Li, Yongchao Long +14 more
similarity 0.58
Abstract

Electrocardiograms (ECGs) may contain physiological information related to hereditary cancer susceptibility, but its relationship with future cancer risk remains unclear. Here, we present ECG2Gene, a two-stage deep-learning framework that derives digital phenotypes related to germline tumor susceptibility from routine 12-lead ECGs and predicts future cancer risk. In Stage 1, carrier status for pathogenic or likely pathogenic variants in ATM, BRIP1, CHEK2, PALB2, BRCA1, and BRCA2 supervises a multitask model that generates six continuous ECG-derived gene scores. In Stage 2, XGBoost integrates these scores with clinical variables to predict subsequent breast and ovarian cancer in women and prostate cancer in men. We also introduce ECG-Wide Association Analysis (EWAS) to characterize associations between ECG-derived gene scores and ECG waveforms. Across the clinical feature combinations evaluated in UK Biobank, the best-performing sex-specific models achieve AUROCs of 0.683, 0.633, and 0.660 for breast, ovarian, and prostate cancer, respectively. In external evaluations, models combining ECG-derived gene scores with age achieve prostate cancer AUROCs of 0.709 and 0.579 among men in the overall China Kadoorie Biobank and MIMIC-IV-ECG cohorts, respectively. ECG2Gene links genetically supervised ECG phenotyping and waveform association analysis to future cancer outcomes, demonstrating the potential of routine ECGs combined with clinical information for non-invasive, opportunistic cancer risk assessment.

0.29

Benchmarking Machine-Learning Classifiers for Neoantigen Immunogenicity Prediction and the Limits of SHAP Interpretability

cs.AI cs.LG ·2026-10-31 ·Ramon Gonzalez
benchmark similarity 0.57
Abstract · 23 pages, 8 figures, 7 tables

Personalized cancer vaccines require prioritizing, among hundreds of candidate mutant peptides, the few that will induce a T-cell response. This study asks what general-purpose machine learning achieves on that task, and whether the features such models identify as important can be trusted. We make three contributions. The first is a benchmark of sixty models: twelve supervised classifier families, each in five configurations, evaluated on the Immunogenic Tumor Specific Neoantigen database (ITSNdb; 199 experimentally validated neoantigens, 129 immunogenic and 70 non-immunogenic). All sixty are compared under one stratified k-fold cross-validation protocol, in which the data used to choose a configuration are never the data used to score it. The second is an interpretability study that combines SHAP with feature ablation. The third is a shuffled-label control that tests whether a SHAP value has been earned. Two results follow, and both run against current practice. First, the classical linear models lead the ranking. The gradient-boosted ensembles and neural networks that dominate recent work bring no advantage. Second, SHAP can fail on high-cardinality categorical features. Ablation establishes the presenting HLA allele as the dominant input and the source gene as dispensable. SHAP reports the opposite, assigning 68.7% to 81.7% of its total value to the source gene in every model that gives each gene its own weight. Shuffling the gene labels at random among the peptides resolves the contradiction: the meaningless column earns the same SHAP value as the real one. That value measures only that ITSNdb contains 173 genes for 199 peptides. We therefore recommend that SHAP values for high-cardinality categorical annotations in cohorts of this size always be reported against such a shuffled-label control, and we describe one in full.

0.35

FedHisto-PAST: Parameter-Efficient Stain-Aware Federated Learning for Cross-Site Lung Histopathology Classification

cs.CV cs.AI ·2026-09-25 ·Muhammad Muhtasim Shahriar, M. M. Golam Hafiz, Saad Aloteibi, Mohammad Ali Moni
similarity 0.57
Abstract · Submitted to Engineering Applications of Artificial Intelligence (Elsevier)

Cross-site lung histopathology classification must account for stain variation, non-IID client data, missing classes, and the cost of adapting large pathology encoders. This study evaluates FedHisto-PAST v2 for three-way classification of adenocarcinoma (ACA), Normal, and squamous cell carcinoma (SCC). FedHisto-PAST v2 combines a frozen HIBOU-B foundation model with parameter-efficient adaptation, stain-conditioned paired-view prediction and feature consistency, reliability-aware prototype learning, and adaptive federated aggregation. Experiments used a five-client, non-IID, raw-data-local simulation with fixed internal evaluation, client-level analysis, component ablations, communication accounting, and a development-influenced exploratory LungHist700 cohort. All principal methods achieved near- ceiling internal performance, which limited discrimination on the fixed split. On LungHist700, FedHisto- PAST v2 achieved a Macro-F1 of 0.728560 and a balanced accuracy of 0.730454. Higher recognition of Normal and SCC was accompanied by lower ACA recall, and calibration remained imperfect. Prediction-level consistency was the only component with a clearly supported independent contribution in the external ablation analysis. Feature consistency and prototype regularization showed no conclusive independent overall gains in Macro-F1. The framework updated 1.253841% of the model parameters. The results provide exploratory cross-dataset evidence for stain-aware, parameter-efficient federation; they do not establish formal privacy, patient-level independence, prospective deployment, or clinical validation.

0.26

Attention-guided classification and tumor localization of combined hepatocellular-cholangiocarcinoma

cs.CV ·2026-10-22 ·Xiaowen Liang, Hélène Cazier, Aurélie Beaufrère, Miguel Albuquerque, Valérie Paradis +1 more
similarity 0.56
Abstract

Combined hepatocellular-cholangiocarcinomas (cHCC-CCA) are a type of cancer that share components of two other primary liver cancers: hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Accurate diagnosis of cHCC-CCA, of which the behavior may resemble that of either HCC or CCA, remains a challenge due to strong intratumoral heterogeneity. Since the prognoses differ between liver cancer types, it is necessary to improve their morphological characterization and recognition in order to accurately identify cHCC-CCA. In this work, we use whole slide images (WSIs) of the two main types of liver cancer (HCC and CCA) and cHCC-CCA, stained with Hematoxylin-Eosin-Safran (HES), to train a classification model that can distinguish between these subtypes and provides a potential solution for localizing different types of tumors in the combined liver cancer images.

0.33